Literature DB >> 1761073

Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

D Deleu1, G Ebinger, Y Michotte.   

Abstract

The clinical effects and pharmacokinetics of orally and intraduodenally administered levodopa, in four patients with Parkinson's disease have been compared. The patients had unpredictable fluctuations in motor function and episodic unresponsiveness to single doses of levodopa. The pharmacokinetic and clinical data of these patients were compared retrospectively with those of Parkinsonian patients with fluctuations in motor performance but with preserved clinical responses to single oral doses of levodopa. There was a threshold plasma concentration of levodopa associated with the "switch on or off" effect. In addition, rapid attainment of this critical plasma concentration was associated with a quicker onset of action and a more prolonged clinical response. All the patients had delayed absorption of levodopa related to delayed and erratic gastric emptying, which contributed to the fluctuation in motor response. In contrast, the patients with fluctuating motor effects but a preserved clinical response after levodopa showed an absorption pattern comparable to that of four patients studied after duodenal delivery of levodopa. It is suggested that there is a subgroup of patients with fluctuating responses due mainly to altered peripheral pharmacokinetics of levodopa. The findings demonstrate the relevance of routine measurements of plasma levodopa in patients with Parkinson's disease in whom there are fluctuations in motor performance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761073     DOI: 10.1007/BF00626368

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier.

Authors:  L A Wade; R Katzman
Journal:  J Neurochem       Date:  1975-12       Impact factor: 5.372

2.  Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.

Authors:  K L Leenders; W H Poewe; A J Palmer; D P Brenton; R S Frackowiak
Journal:  Ann Neurol       Date:  1986-08       Impact factor: 10.422

Review 3.  Central mechanisms and levodopa response fluctuations in Parkinson's disease.

Authors:  M M Mouradian; T N Chase
Journal:  Clin Neuropharmacol       Date:  1988-08       Impact factor: 1.592

4.  Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.

Authors:  E Melamed; V Bitton; O Zelig
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

5.  Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.

Authors:  J I Sage; L Schuh; R E Heikkila; R C Duvoisin
Journal:  Clin Neuropharmacol       Date:  1988-02       Impact factor: 1.592

6.  Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients.

Authors:  M N Rossor; J Watkins; M J Brown; J L Reid; C T Dollery
Journal:  J Neurol Sci       Date:  1980-06       Impact factor: 3.181

7.  Systemic activity of orally administered L-dopa in the elderly Parkinson patient.

Authors:  M A Evans; E J Triggs; G A Broe; N Saines
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

8.  Simultaneous determination of levodopa, carbidopa, 3-O-methyldopa and dopamine in plasma using high-performance liquid chromatography with electrochemical detection.

Authors:  Y Michotte; M Moors; D Deleu; P Herregodts; G Ebinger
Journal:  J Pharm Biomed Anal       Date:  1987       Impact factor: 3.935

9.  Control of on/off phenomenon by continuous intravenous infusion of levodopa.

Authors:  N Quinn; J D Parkes; C D Marsden
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

10.  Dopamine D2 receptor density remains constant in treated Parkinson's disease.

Authors:  M Guttman; P Seeman; G P Reynolds; P Riederer; K Jellinger; W W Tourtellotte
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

View more
  11 in total

1.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study.

Authors:  D Deleu; S Sarre; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

3.  Relative bioavailability of chlorothiazide from mucoadhesive compacts in pigs.

Authors:  Karunakar Neelam; Ravichandran Mahalingam; Raj Birudaraj; Tom Alfredson; Pratap Anne; Xiaoling Li; Bhaskara R Jasti
Journal:  AAPS PharmSciTech       Date:  2009-11-10       Impact factor: 3.246

4.  Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.

Authors:  Lixin Wang; Sachiko Mogami; Hiroshi Karasawa; Chihiro Yamada; Seiichi Yakabi; Koji Yakabi; Tomohisa Hattori; Yvette Taché
Journal:  Peptides       Date:  2014-03-11       Impact factor: 3.750

5.  Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.

Authors:  E Bredberg; D Nilsson; K Johansson; S M Aquilonius; B Johnels; C Nyström; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  H Karasawa; C Pietra; C Giuliano; S Garcia-Rubio; X Xu; S Yakabi; Y Taché; L Wang
Journal:  Neurogastroenterol Motil       Date:  2014-10-19       Impact factor: 3.598

8.  Evaluation of polyethylene oxide compacts as gastroretentive delivery systems.

Authors:  Ravichandran Mahalingam; Bhaskara Jasti; Raj Birudaraj; Dimitrios Stefanidis; Robert Killion; Tom Alfredson; Pratap Anne; Xiaoling Li
Journal:  AAPS PharmSciTech       Date:  2009-01-16       Impact factor: 3.246

9.  Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation.

Authors:  S Harder; H Baas; N Bergemann; L Demisch; S Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

10.  The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle.

Authors:  D Deleu; S Sarre; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.